Loading...
Please wait, while we are loading the content...
Similar Documents
PARP inhibitor combinations in prostate cancer
| Content Provider | SAGE Publishing |
|---|---|
| Author | Pezaro, Carmel |
| Copyright Year | 2020 |
| Abstract | Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that are based on purported synergies in treatment effect. While the initial single-agent development focused on men with identified deficiencies in DNA-repair pathways, broader patient populations are being considered for combination approaches. This review summarizes the current clinical development of PARP inhibitors and explores the rationale for novel combination strategies. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/1758835919897537?download=true |
| ISSN | 17588359 |
| Volume Number | 12 |
| Journal | Therapeutic Advances in Medical Oncology (TAM) |
| e-ISSN | 17588359 |
| DOI | 10.1177/1758835919897537 |
| Language | English |
| Publisher | Sage Publications UK |
| Publisher Date | 2020-03-18 |
| Publisher Place | London |
| Access Restriction | Open |
| Rights Holder | © The Author(s), 2020 |
| Subject Keyword | DNA-damage repair PARP combinations synthetic lethality PARP inhibitor prostate cancer |
| Content Type | Text |
| Resource Type | Article |
| Subject | Oncology |